Jeetinder Singh Mahal - Jun 13, 2023 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Role: Chief Operating Officer, Chief Financial Officer and Corporate Secretary
Signature: /s/ Jeet Mahal
Stock symbol: JSPR
Transactions as of: Jun 13, 2023
Transactions value $: -$8,525
Form type: 4
Date filed: 6/13/2023, 08:54 PM
Previous filing: Apr 14, 2023
Next filing: Oct 13, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JSPR	Voting Common Stock	Options Exercise	$6.39K	+9K	+3.13%	$0.71	296K	Jun 13, 2023	Direct	F1
transaction	JSPR	Voting Common Stock	Sale	-$14.9K	-9K	-3.04%	$1.66	287K	Jun 13, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JSPR	Stock Option (right to buy)	Options Exercise	$0	+9K	+5.46%	$0.00	174K	Jun 13, 2023	Voting Common Stock	9K	$0.71	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.69, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
F3	25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares have vested and shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Remarks:

Chief Operating Officer, Chief Financial Officer and Corporate Secretary